Drug intelligence / Profile preview

Iodohippurate sodium I-123

Development stage
Unknown
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Iodohippurate sodium I-123 is a radiopharmaceutical diagnostic agent used primarily to evaluate effective renal plasma flow (ERPF) and kidney function. It consists of o-iodohippuric acid labeled with the radioactive isotope iodine-123. After intravenous administration, it is rapidly cleared from the bloodstream by the kidneys and excreted in urine, allowing for dynamic imaging of renal perfusion and function using gamma cameras or SPECT. The mechanism of action involves filtration and tubular secretion by the kidneys; its pharmacokinetics make it suitable for quantitative assessment of renal plasma flow. It is not used therapeutically but as a diagnostic tool in nuclear medicine[1][2][3][7].

Brand names
NephroflowHippuran I 123
Other names
o-iodohippuric acid I-123ortho-iodohippurate sodium I-123
02

Targets

OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)

Beyond the preview

Go deeper on Iodohippurate sodium I-123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iodohippurate sodium I-123.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call